Want to see HK:1498 full AI Analyst Report?
Top Page
PuraPharm Corp. Ltd.
(1498)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$0.23
▼(-33.43% Downside)
Action:Reiterated
Date:08/10/26
The score is primarily held back by weak financial performance—multi-year net losses, shrinking revenue, and high leverage—despite strong gross margins and recent positive free cash flow. Technicals add further pressure as the stock trades below major moving averages with negative MACD. Valuation is difficult to support due to the negative P/E and no dividend yield data.
Positive Factors
Strong Gross Margins
Gross margins near 53% indicate that the company retains meaningful value after production costs. If maintained, this provides a foundation for funding commercialization, supporting product economics, and improving profitability should revenue stabilization and operating discipline eventually lift the business above its current losses.
Negative Factors
Persistent Net Losses
Recurring EBIT and net losses over five years show that strong gross profitability has not translated into sustainable bottom-line earnings. The continuing negative margin reduces retained capital, limits self-funded expansion, and leaves the company dependent on improvement in operating performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Gross margins near 53% indicate that the company retains meaningful value after production costs. If maintained, this provides a foundation for funding commercialization, supporting product economics, and improving profitability should revenue stabilization and operating discipline eventually lift the business above its current losses.
Read all positive factors
PuraPharm Corp. Ltd. (1498) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$128.92M
Dividend Yield0.48%
Average Volume (3M)61.29K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue Growth-6.71%
EPS Growth43.14%
CountryHK
Employees460
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.06
Shares Outstanding535,897,640
10 Day Avg. Volume31,250
30 Day Avg. Volume61,291
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.14
Price to Sales (P/S)0.44
P/FCF Ratio5.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PuraPharm Corp. Ltd. Business Overview & Revenue Model
Company Description
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Ma...
PuraPharm Corp. Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 323.49M | 336.11M | 382.09M | 406.86M | 448.07M | 659.59M |
| Gross Profit | 176.58M | 180.16M | 205.14M | 216.63M | 260.59M | 421.85M |
| EBITDA | 38.05M | 28.30M | 36.42M | -26.31M | -46.34M | -40.03M |
| Net Income | -27.66M | -35.22M | -35.44M | -106.08M | -120.21M | -121.88M |
Balance Sheet | ||||||
| Total Assets | 699.82M | 693.76M | 715.73M | 843.96M | 1.02B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 12.23M | 21.18M | 12.79M | 47.22M | 91.36M | 85.05M |
| Total Debt | 370.62M | 351.14M | 363.76M | 424.77M | 503.16M | 531.96M |
| Total Liabilities | 574.86M | 560.59M | 604.53M | 690.73M | 757.18M | 803.13M |
| Stockholders Equity | 124.08M | 130.48M | 111.20M | 153.24M | 258.29M | 401.56M |
Cash Flow | ||||||
| Free Cash Flow | -26.91M | 25.69M | 89.18M | 57.95M | 42.29M | -45.89M |
| Operating Cash Flow | -25.16M | 28.52M | 103.98M | 79.61M | 65.85M | -39.33M |
| Investing Cash Flow | -4.04M | 24.12M | -11.71M | -18.20M | -25.45M | 6.00M |
| Financing Cash Flow | -802.00K | -46.34M | -86.43M | -122.39M | -12.94M | -13.87M |
PuraPharm Corp. Ltd. Technical Analysis
Negative
0.35
Price Trends
0.27
Negative
0.28
Negative
0.30
Negative
Market Momentum
>-0.01
Positive
39.00
Neutral
20.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1498, the sentiment is Negative. The current price of 0.35 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.27, and above the 200-day MA of 0.30, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.00 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1498.
PuraPharm Corp. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$744.82M | 7.47 | 13.59% | 7.74% | 10.63% | 39.44% | |
68 Neutral | HK$662.44M | 3.84 | 8.02% | 5.32% | 7.05% | 22.46% | |
64 Neutral | HK$1.40B | 5.93 | 16.70% | 17.22% | -5.37% | -18.03% | |
54 Neutral | HK$220.40M | -0.20 | -154.56% | ― | -7.12% | -523.61% | |
53 Neutral | HK$434.61M | 106.94 | 0.34% | 84.69% | -8.30% | -44.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$128.92M | -4.24 | -21.73% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:1498
PuraPharm Corp. Ltd.
0.24
-0.20
-45.23%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
-0.02
-16.13%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.39
-0.04
-10.47%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.09
-0.75
-40.84%
HK:0239
Pak Fah Yeow International Limited
2.39
0.13
5.94%
HK:6896
Golden Throat Holdings Group Co Ltd
1.98
-1.25
-38.84%
PuraPharm Corp. Ltd. Corporate Events
PuraPharm Calls October EGM to Approve Change of Auditor
Oct 8, 2026
PuraPharm Corporation Limited has called an extraordinary general meeting in Hong Kong on 30 October 2026 to seek shareholder approval for changes to its external auditor. The company will ask investors to ratify the resignation of BDO Limited and...
PuraPharm Moves to Replace Auditor BDO Over Fee Considerations
Sep 15, 2026
PuraPharm Corporation Limited has announced a proposed change of auditor, with BDO Limited resigning effective at the conclusion of the forthcoming shareholders’ general meeting after the Board moved to adjust audit arrangements due to fee c...
PuraPharm Narrows Interim Loss Despite Revenue Decline
Aug 26, 2026
PuraPharm reported interim revenue of HK$159.7 million for the six months ended 30 June 2026, down 7.3% year-on-year, with gross profit slipping 3% to HK$92.3 million. The core Hong Kong and overseas CCMG segment grew modestly by 2%, while Chinese...
PuraPharm Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 14, 2026
PuraPharm Corporation Limited has scheduled a board meeting for 26 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The board will also decide on the publication of the interim results anno...
PuraPharm Names New Company Secretary as Governance Roles Shift
Jul 17, 2026
PuraPharm Corporation Limited has announced a change in its core governance functions, with company secretary and authorised representative Ms. Chan Charmayne stepping down from her roles effective 18 July 2026. The board noted that her departure ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.